Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

New drug shows impressive results against lipoprotein(a), a genetic form of cholesterol that affects millions but remains ...

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be untreatable, for up to one year.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

The focus is on a drug called Lepodisiran, that could target certain factors that increase risk of heart attacks and strokes.

High levels of a chemical that is believed to be behind sudden and inexplicable heart attacks and strokes could soon have ...

An estimated 64 million Americans have elevated levels of lipoprotein(a), or Lp(a), a type of cholesterol that can increase the risk of heart attack and other cardiovascular problems. Having high ...

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

A new study published in the recent issue of Atherosclerosis journal showed that lipoprotein(a) [Lp(a)] levels may change the ...